艾力斯深度报告：商业化成绩显著产品矩阵持续拓宽

甬兴证券有限公司2025-07-12

核心观点深耕非小细胞肺癌靶向药领域，商业化成绩显著艾力斯为专注于肿瘤治疗领域的创新药企业，已在非小细胞肺癌靶向药领域构建了优势研发管线，核心产品伏美替尼NSCLC 一线和二线适应症均已国内上市并纳入医保。得益于伏美替尼的快速放量，2021年以来公司利润端保持快速增长态势。伏美替尼具备脑转强效、疗效优异、安全性佳、治疗窗宽特点，多项适应症拓展持续推进伏美替尼为公司原研第三代EGFR-TKI，在已获批...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550771995?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-12 11:42","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550771995","market":"sh","top_or_hot":-1,"title":"艾力斯深度报告：商业化成绩显著 产品矩阵持续拓宽","media":"甬兴证券有限公司","content":"<div>\n<p>核心观点深耕非小细胞肺癌靶向药领域，商业化成绩显著艾力斯为专注于肿瘤治疗领域的创新药企业，已在非小细胞肺癌靶向药领域构建了优势研发管线，核心产品伏美替尼NSCLC 一线和二线适应症均已国内上市并纳入医保。得益于伏美替尼的快速放量，2021年以来公司利润端保持快速增长态势。伏美替尼具备脑转强效、疗效优异、安全性佳、治疗窗宽特点，多项适应症拓展持续推进伏美替尼为公司原研第三代EGFR-TKI，在已获批...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712114257953f8b65&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾力斯深度报告：商业化成绩显著 产品矩阵持续拓宽</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾力斯深度报告：商业化成绩显著 产品矩阵持续拓宽\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-12 11:42 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712114257953f8b65&s=b><strong>甬兴证券有限公司</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>核心观点深耕非小细胞肺癌靶向药领域，商业化成绩显著艾力斯为专注于肿瘤治疗领域的创新药企业，已在非小细胞肺癌靶向药领域构建了优势研发管线，核心产品伏美替尼NSCLC 一线和二线适应症均已国内上市并纳入医保。得益于伏美替尼的快速放量，2021年以来公司利润端保持快速增长态势。伏美替尼具备脑转强效、疗效优异、安全性佳、治疗窗宽特点，多项适应症拓展持续推进伏美替尼为公司原研第三代EGFR-TKI，在已获批...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712114257953f8b65&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688578","symbol_name":"艾力斯","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712114257953f8b65&s=b","article_id":"2550771995","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712114257953f8b65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550771995","pubTimestamp":1752291776,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"我们预计上述多项适应症若顺利获批，伏美替尼商业化销售仍将具备强劲增长动力。公司深耕肺癌市场，商业化成绩显著，考虑伏美替尼仍有20 外插与辅助治疗等适应症拓展空间以及与可比公司平均对比PE 相对较低，维持“买入”评级。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688578":"艾力斯","BK0239":"医药制造"},"translate_title":"Ellis in-depth report: Remarkable commercialization achievements, product matrix continues to expand","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688578":1},"content_text":"核心观点深耕非小细胞肺癌靶向药领域，商业化成绩显著艾力斯为专注于肿瘤治疗领域的创新药企业，已在非小细胞肺癌靶向药领域构建了优势研发管线，核心产品伏美替尼NSCLC 一线和二线适应症均已国内上市并纳入医保。得益于伏美替尼的快速放量，2021年以来公司利润端保持快速增长态势。伏美替尼具备脑转强效、疗效优异、安全性佳、治疗窗宽特点，多项适应症拓展持续推进伏美替尼为公司原研第三代EGFR-TKI，在已获批EGFR 突变NSCLC一/二线疗效显著，安全性优势明显。此外公司积极拓展伏美替尼适应症，1）在脑转移中表现出强效，III 期试验IND 已于2024 年获得批准；2）术后辅助治疗适应症III 注册临床研究已于2024 年上半年完成患者入组；3）针对EGFR PACC 突变晚期NSCLC 疗效突出，对比化疗III 期临床已经启动；4）20 外显子插入NSCLC 二线适应症有望2025 年提交NDA，一线适应症预计2027 年获批上市。我们预计上述多项适应症若顺利获批，伏美替尼商业化销售仍将具备强劲增长动力。持续丰富产品梯队，戈来雷塞等有望助力销售除伏美替尼外，公司还通过引进方式扩充产品梯队。自加科思引进的戈来雷塞用于KRAS G12C 突变二线NSCLC 的NDA 申请已于2024年5 月获得优先审评，根据加科思2024 年交流材料预计于2025Q2 获批上市，对比竞品具备安全性优势；自基石药业引进的普拉替尼降价工作已完成，地产化顺利推进中。公司在研管线还布局有新一代EGFR抑制剂和自研KRAS G12D 抑制剂。投资建议我们预计公司25/26/27 年收入分别为45.3/55.4/66.2 亿元，同比增长27.4%/22.1%/19.6%；归母净利润为17.7/20.9/25.0 亿元，同比增长23.5%/18.1%/19.7%，对应PE 为24/20/17 倍。公司深耕肺癌市场，商业化成绩显著，考虑伏美替尼仍有20 外插与辅助治疗等适应症拓展空间以及与可比公司平均对比PE 相对较低，维持“买入”评级。风险提示1）创新药临床推进进度不及预期；2）创新药临床数据不及预期；3）创新药上市后销售情况不及预期","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550771995","isCrawlerRequest":true}

艾力斯深度报告：商业化成绩显著 产品矩阵持续拓宽

精彩评论

艾力斯深度报告：商业化成绩显著产品矩阵持续拓宽